Uzma Haider, MD
Endocrinology, Diabetes & Metabolism · Hemet, CANPI 1386838696
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Amgen accounts for 86.9% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $20,400, more than ten times the $110 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $112.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$27K
- Corcept Therapeutics$808
- Xeris Pharmaceuticals, Inc.$577
- Abbott$247
- Bayer$227
- Kyowa Kirin, Inc.$198
- plus $2K from 29 others
What the payments were for
- Consulting fees$7,42524%
- Speaking & faculty fees$14,40047%
- Travel & lodging$2,8479%
- Food & beverage$5,87719%
- Education$1691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 103 | $26,700 |
| Corcept Therapeutics | 33 | $808 |
| Xeris Pharmaceuticals, Inc. | 27 | $577 |
| Abbott | 8 | $247 |
| Bayer | 11 | $227 |
| Kyowa Kirin, Inc. | 7 | $198 |
| Insulet Corporation | 6 | $171 |
| Medtronic(2 entities) | 6 | $161 |
| Lilly USA, LLC | 8 | $135 |
| Verity Pharmaceuticals Inc. | 5 | $123 |
| Ascendis Pharma Endocrinology Inc | 4 | $120 |
| Tandem Diabetes Care, Inc. | 6 | $119 |
| Novartis | 6 | $116 |
| Sequel Med Tech, LLC | 2 | $108 |
| Madrigal Pharmaceuticals | 3 | $104 |
| AstraZeneca | 6 | $93 |
| Boehringer Ingelheim | 4 | $85 |
| Recordati_rare_diseases_inc. | 4 | $81 |
| Dexcom, Inc. | 2 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $61 |
| Novo Nordisk | 3 | $55 |
| Soleno Therapeutics, Inc. | 2 | $44 |
| BETA Bionics, Inc. | 2 | $43 |
| Echosens North America, Inc. | 1 | $31 |
| Sanofi | 1 | $29 |
| Mannkind Corporation | 2 | $27 |
| Chiesi USA, Inc. | 1 | $26 |
| Tolmar, Inc. | 1 | $25 |
| Antares Pharma, Inc. | 1 | $24 |
| AbbVie | 1 | $24 |
| Cequr Corporation | 1 | $23 |
| Nevro Corp. | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $19 |
| GSK | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,718 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 136 | $153,857 |
| OzempicSemaglutide | 106 | $117,853 |
| JardianceEmpagliflozin | 106 | $105,220 |
| RybelsusSemaglutide | 42 | $55,450 |
| FarxigaDapagliflozin Propanediol | 56 | $46,499 |
| MounjaroTirzepatide | 36 | $42,726 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $26,324 |
| Humalog Kwikpen U-100Insulin Lispro | 57 | $17,180 |
| Victoza 3-PakLiraglutide | 15 | $12,523 |
| HumalogInsulin Lispro | 40 | $10,630 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $10,142 |
| DapagliflozinDapagliflozin Propanediol | 11 | $10,024 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $9,805 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $7,667 |
| Repatha SyringeEvolocumab | 12 | $6,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $135 | $207,213212 claims |
| Novo NordiskOzempic, Rybelsus | $55 | $173,303148 claims |
| Boehringer IngelheimJardiance | $85 | $105,220106 claims |
| AstraZenecaFarxiga | $93 | $46,49956 claims |
| Sanofi-aventis U.S. LLCLantus | $61 | $3,21516 claims |
| AbbVieSynthroid | $24 | $1,92332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Hemet
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.